Last reviewed · How we verify
Midazolam - active comparator
Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, depressing central nervous system activity.
Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, depressing central nervous system activity. Used for Procedural sedation and anxiolysis, Acute seizure management, Preoperative anxiety.
At a glance
| Generic name | Midazolam - active comparator |
|---|---|
| Also known as | Dormicum |
| Sponsor | Assaf-Harofeh Medical Center |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology, Anesthesia, Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Midazolam binds to GABA-A receptors in the central nervous system, potentiating the effect of the inhibitory neurotransmitter GABA. This results in sedation, anxiolysis, muscle relaxation, and anticonvulsant effects. The drug is commonly used for procedural sedation, anxiety management, and seizure control in acute settings.
Approved indications
- Procedural sedation and anxiolysis
- Acute seizure management
- Preoperative anxiety
- Sedation in intensive care settings
Common side effects
- Sedation
- Respiratory depression
- Hypotension
- Dizziness
- Headache
- Amnesia
Key clinical trials
- Ketamine, SGB and Combination Treatment for TBI (PHASE2)
- A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants (PHASE1)
- Analgesia-First Sedation in Trauma Patients (NA)
- Ketamine in OCD: Efficacy and Effects on Stress and Cognition (NA)
- Midazolam Efficacy/Safety in Pre-Eclamptic C-Section Sedation (NA)
- Circumferential Pulmonary Vein Isolation Plus Transition Zone Modification in Atrial Fibrillation Patients Without Low-Voltage Areas (NA)
- Comparing in Dexmedetomidine With po/pr Midazolam for Procedural Sedation in the Pediatric Emergency Department (PHASE4)
- Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Midazolam - active comparator CI brief — competitive landscape report
- Midazolam - active comparator updates RSS · CI watch RSS
- Assaf-Harofeh Medical Center portfolio CI